Rumination Syndrome Market Research Report – Forecast to 2027

Rumination Syndrome Market: By Diagnosis (Esophagogastroduodenoscopy, Gastric Emptying), by Treatment (Behavior Therapy, Medication and Others), by End-User (Hospitals, Gastroenterology Clinics, Research Centers and Others) - Global Forecast till 2027

ID: MRFR/Pharma/4589-HCR | August 2022 | Region: Global | 100 Pages         

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Rumination Syndrome Market, by Diagnosis & Treatment

6.1 Introduction

6.2 Diagnosis

6.2.1 Esophagogastroduodenoscopy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.2.1.1 Flexible endoscope

6.2.2 Gastric Emptying

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.2.2.1 CT scan

6.3 Treatment

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.3.1 Behavior therapy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.3.2 Medication

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

3.3.2.1 Proton Pump inhibitors

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.3.2.1 Esomeprazole

6.3.2.2 Omeprazole

6.3.2.3 Pantoprazole

6.3.2.4 Lansoprazole

6.3.2.5 Dexlansoprazole

6.3.2.6 Rabeprazole

6.3.2.7 Others

7. Global Rumination Syndrome Market, by End-User

7.1 Introduction

7.2 Gastroenterology Clinics

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

7.3 Hospitals

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

7.4 Research Centers

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

7.5 Others

8. Global Rumination Syndrome Market, by Region

8.1 Introduction

8.2 Americas

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.2.1 North America

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.2.1.1 U.S.

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.2.1.2 Canada

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.2.2 South America

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3 Europe

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1 Western Europe

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.1 Germany

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.2 France

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.3 U.K.

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.4 Italy

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.5 Spain

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.1.6 Rest of Western Europe

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.3.2 Eastern Europe

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4 Asia Pacific

β€’ Market Estimates & Forecast, by Country, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.1 Japan

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.2 China

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.3 India

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.4 Australia

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.5 Republic of Korea

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.4.6 Rest of Asia Pacific

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.5 The Middle East & Africa

β€’ Market Estimates & Forecast, by Region, 2020–2027

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.5.1 Middle East

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

8.5.2 Africa

β€’ Market Estimates & Forecast, by Diagnosis, 2020–2027

β€’ Market Estimates & Forecast, by Treatment, 2020–2027

β€’ Market Estimates & Forecast, by End-User, 2020–2027

9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

9.3.1 Key Developments

10 Company Profiles

10.1 Pfizer Inc.

10.1.1 Company Overview

10.1.2 Product and Services Overview

10.1.3 Financials

10.1.4 SWOT Analysis

10.2 Valent Pharmaceuticals

10.2.1 Company Overview

10.2.2 Product and Services Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Medtronic

10.3.1 Company Overview

10.3.2 Product and Services Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Astra Zeneca

10.4.1 Company Overview

10.4.2 Product and Services/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Eisai Co. Ltd.

10.5.1 Company Overview

10.5.2 Product and Services Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.6 Takeda Pharmaceuticals

10.6.1 Company Overview

10.6.2 Product and Services Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.7 Allergan Plc.

10.7.1 Overview

10.7.2 Product and Services Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Novo Nordisk A/S

10.8.1 Overview

10.8.2 Product and Services Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 Johnson & Johnson

10.9.1 Overview

10.9.2 Product and Services Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Bayer AG

10.10.1 Overview

10.10.2 Product and Services Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.11 Otsuka Pharmaceutical Co. Ltd.

10.11.1 Overview

10.11.2 Product and Services Overview

10.11.3 Financials

10.11.4 Key Developments

10.12.5 SWOT Analysis

10.12 Others

11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of Rumination Syndrome Industry

12 Appendix

LIST OF TABLES

Table 1 Rumination Syndrome Industry Synopsis, 2020–2027

Table 2 Global Rumination Syndrome Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Rumination Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 5 Global Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 7 North America Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 8 North America Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 9 North America Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 11 US Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 12 US Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 14 Canada Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 15 Canada Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 17 South America Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 South America Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 20 Europe Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 21 Europe Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 23 Western Europe Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 24 Western Europe Rumination Syndrome Market, by End-Users, 2020–2027, (USD Million)

Table 25 Eastern Europe Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 26 Eastern Europe Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 27 Eastern Europe Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia Pacific Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 29 Asia Pacific Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Asia Pacific Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 31 Middle East & Africa Rumination Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 32 Middle East & Africa Rumination Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 33 Middle East & Africa Rumination Syndrome Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Rumination Syndrome Market

Figure 3 Segmentation Market Dynamics for Rumination Syndrome Market

Figure 4 Global Rumination Syndrome Market Share, by Treatment 2020

Figure 5 Global Rumination Syndrome Market Share, by Diagnosis 2020

Figure 6 Global Rumination Syndrome Market Share, by End-Users, 2020

Figure 7 Global Rumination Syndrome Market Share, by Region, 2020

Figure 8 North America Rumination Syndrome Market Share, by Country, 2020

Figure 9 Europe Rumination Syndrome Market Share, by Country, 2020

Figure 10 Asia Pacific Rumination Syndrome Market Share, by Country, 2020

Figure 11 Middle East & Africa Rumination Syndrome Market Share, by Country, 2020

Figure 12 Global Rumination Syndrome Market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer Inc.: Key Financials

Figure 14 Pfizer Inc.: Segmental Revenue

Figure 16 Pfizer Inc.: Geographical Revenue

Figure 17 Valent Pharmaceuticals: Key Financials

Figure 18 Valent Pharmaceuticals: Segmental Revenue

Figure 19 Valent Pharmaceuticals: Geographical Revenue

Figure 20 Medtronic: Key Financials

Figure 21 Medtronic: Segmental Revenue

Figure 22 Medtronic: Geographical Revenue

Figure 23 Astra Zeneca: Key Financials

Figure 24 Astra Zeneca: Segmental Revenue

Figure 25 Astra Zeneca: Geographical Revenue

Figure 26 Eisai Co. Ltd.: Segmental Revenue

Figure 27 Eisai Co. Ltd.: Geographical Revenue

Figure 28 Eisai Co. Ltd: Key Financials

Figure 29 Takeda Pharmaceuticals. Segmental Revenue

Figure 30 Takeda Pharmaceuticals. Geographical Revenue

Figure 31 Takeda Pharmaceuticals: Key Financials

Figure 32 Allergan Plc.: Key Financials

Figure 33 Allergan Plc.: Segmental Revenue

Figure 34 Allergan Plc.: Geographical Revenue

Figure 35 Novo Nordisk A/S. Key Financials

Figure 36 Novo Nordisk A/S. Segmental Revenue

Figure 37 Novo Nordisk A/S. Geographical Revenue

Figure 38 Johnson & Johnson.: Key Financials

Figure 39 Johnson & Johnson.: Segmental Revenue

Figure 40 Johnson & Johnson.: Geographical Revenue

Figure 41 Bayer AG. Key Financials

Figure 42 Bayer AG. Segmental Revenue

Figure 43 Bayer AG. Geographical Revenue

Figure 44 Otsuka Pharmaceutical Co. Ltd. Key Financials

Figure 45 Otsuka Pharmaceutical Co. Ltd. Segmental Revenue

Figure 46 Otsuka Pharmaceutical Co. Ltd. Geographical Revenue

Rumination Syndrome Market Speak to Analyst Request a Free Sample

Rumination Syndrome Market Forecast


Rumination syndrome market is expected to grow at a CAGR of 6.1% during the forecast period. The market is majorly driven by the increasing prevalence of smoking population and rising cases of reflux disorders during pregnancy. Smoking may cause dryness of the mouth thus leading to less production of saliva, which may induce symptoms of heartburn. As saliva offsets the acid, a cigarette makes it harder for the body to guard against these acids which is some of the causes of the rumination syndrome. Additionally, factors such as increasing government and private funding to support research activities are likely to boost the market growth during the forecast period, 2018–2023.


However, the presence of misbranded and spurious drugs may hamper the growth of the market during the assessment period 2018–2023. Moreover, the presence of a number of market players and the saturation in the market have increased the introduction of many misbranded and spurious drugs. These drugs are either not effective or very low in potency which may negatively impact the market during the forecast period.


Market Segmentation


The rumination syndrome market is segmented by diagnosis, treatment, and end-user. Diagnosis is further sub-segmented into esophagogastroduodenoscopy, gastric emptying, and others.


Furthermore, on the basis of treatment, the market is segmented into behavior therapy and medication. The medication segment has been sub-segmented into proton pump inhibitors and others. Proton pump inhibitors are sub-segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.


Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American rumination syndrome market is segmented into two regions, namely, North America and South America. North America is further segmented into the U.S. and Canada. Europe is further segmented into Western Europe and Eastern Europe. Western Europe consists of countries such as Germany, the U.K., France, Spain, Italy, and the rest of Western Europe.


Key Players in the Rumination Syndrome Market


Some of the key players in this market are Pfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co. Ltd, and others.


Regional Market Summary


According to MRFR analysis, North America holds the largest market and is mainly driven by the presence of major market players, high healthcare spending, and continuous technological development. Furthermore, established market players in the market lead to globalization by pushing new products and services into developing countries and emerging economies. South America is expected to be the fastest growing market for the American rumination syndrome market due to technologically advanced devices for diagnosis and increasing demand for treatment options of chronic diseases during the forecast period 2018–2023.


The European rumination syndrome market is expected to exhibit growth during the forecast period, 2018 to 2023 with an increasing emphasis on research and developmental activities for improvement in diagnosis and treatment methods. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, increasing expenditure on healthcare by these countries in Europe also accelerates the growth of the market.


Asia Pacific is expected to grow at a faster pace during the forecast period, 2018–2023. The growth is majorly attributed to the increasing patient population in developing countries and increasing investments in the healthcare sector. For instance, India is experiencing high demand for GI and related disorder drugs. Moreover, major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for GI diseases to meet the growing demand. Furthermore, healthcare in Malaysia is segmented into a government universal healthcare scheme and a private healthcare system. The private healthcare system is growing rapidly, especially, in urban areas due to increasing wealthy and middle-class population, geriatric population, urbanization, and high-quality healthcare and medicines. Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the rumination syndrome market.


The Middle Eastern and African market for the rumination syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatments of chronic conditions and the flourishing growth of the medical devices market. In the African region, the awareness about the rumination syndrome is fueling the growth of the market.  


Research Methodology


Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.


Rumination Syndrome Market, by Diagnosis



  • Esophagogastroduodenoscopy

  • Flexible Endoscope

  • Gastric Emptying

  • CT scan


Rumination Syndrome Market, by Treatment



  • Behavior therapy

  • Medication


    • Proton pump inhibitors


      • Esomeprazole

      • Omeprazole

      • Pantoprazole

      • Lansoprazole

      • Dexlansoprazole

      • Rabeprazole

      • Others




Rumination Syndrome Market, by End-User



  • Gastroenterology Clinics

  • Hospitals

  • Research Centers

  • Others


Rumination Syndrome Market, by Region


North America



  • U.S.

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific


Middle East and Africa



  • Middle East

  • Africa


Market Players



  • Pfizer Inc.

  • Valent Pharmaceuticals

  • Medtronic

  • Astra Zeneca

  • Eisai Co. Ltd.

  • Takeda Pharmaceuticals

  • Allergan Plc.

  • Novo Nordisk A/S

  • Johnson & Johnson

  • Bayer AG

  • Otsuka Pharmaceutical Co. Ltd.

  • Others


Intended Audience



  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Major treatments against rumination syndrome include behavioral therapy, medication, and others.

Global rumination syndrome market is expected to exhibit a strong 6.1% CAGR over the forecast period till 2027.

The growing popularity of smoking is likely to be a major driver for the rumination syndrome market.

North America holds the largest share in the global rumination syndrome market.

Leading players in the rumination syndrome market include Medtronic, AstraZeneca, and Takeda Pharmaceuticals, among others.